Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy
David A. Bond, Jeffrey M. Switchenko, Diego Villa, et al.
Blood Advances (2021) Vol. 5, Iss. 23, pp. 5179-5189
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium
Yucai Wang, Preetesh Jain, Frederick L. Locke, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 14, pp. 2594-2606
Open Access | Times Cited: 106
Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments
Preetesh Jain, Michael Wang
American Journal of Hematology (2022) Vol. 97, Iss. 5, pp. 638-656
Closed Access | Times Cited: 95
Treatment approaches for patients with TP53-mutated mantle cell lymphoma
Thomas E. Lew, Adrian Minson, Michael Dickinson, et al.
The Lancet Haematology (2023) Vol. 10, Iss. 2, pp. e142-e154
Closed Access | Times Cited: 17
What clinicians should know about surrogate end points in hematologic malignancies
C. Bommier, Matthew J. Maurer, Jérôme Lambert
Blood (2024) Vol. 144, Iss. 1, pp. 11-20
Closed Access | Times Cited: 6
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL
Maria Chiara Tisi, Riccardo Moia, Caterina Patti, et al.
Blood Advances (2023) Vol. 7, Iss. 15, pp. 3916-3924
Open Access | Times Cited: 14
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma
Yazeed Sawalha, Subir Goyal, Jeffrey M. Switchenko, et al.
Blood Advances (2023) Vol. 7, Iss. 13, pp. 2983-2993
Open Access | Times Cited: 11
Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma
Diego Villa, Aixiang Jiang, Carlo Visco, et al.
Blood Advances (2023) Vol. 7, Iss. 16, pp. 4576-4585
Open Access | Times Cited: 10
Biological and Clinical Determinants Shaping Heterogeneity in Mantle Cell Lymphoma
Cristina López, Elisabeth Silkenstedt, Martin Dreyling, et al.
Blood Advances (2024) Vol. 8, Iss. 14, pp. 3652-3664
Open Access | Times Cited: 3
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study
Clémentine Sarkozy, Loïc Chartier, Vincent Ribrag, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma
Reem Karmali, Jeremy S. Abramson, Deborah M. Stephens, et al.
Blood Advances (2023) Vol. 7, Iss. 23, pp. 7361-7368
Open Access | Times Cited: 8
Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020
Minna Harmanen, Mika Hujo, Reijo Sund, et al.
British Journal of Haematology (2022) Vol. 201, Iss. 1, pp. 64-74
Open Access | Times Cited: 12
SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024
Andrew Ip, Alexandra Della Pia, André Goy
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 8, pp. 491-505
Closed Access | Times Cited: 2
Real‐world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis
Ping Yang, Qingqing Cai, Wei Zhang, et al.
Cancer Medicine (2023) Vol. 12, Iss. 12, pp. 13204-13216
Open Access | Times Cited: 6
Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
Giulia Bega, Jacopo Olivieri, Marcello Riva, et al.
Cancers (2021) Vol. 13, Iss. 23, pp. 6089-6089
Open Access | Times Cited: 12
Recent advances in genomics and therapeutics in mantle cell lymphoma
Tingxun Lu, Jie Zhang, Jenna McCracken, et al.
Cancer Treatment Reviews (2023) Vol. 122, pp. 102651-102651
Closed Access | Times Cited: 4
Genetic and prognostic analysis of blastoid and pleomorphic mantle cell lymphoma: a multicenter analysis in China
Ping Yang, Shuozi Liu, Chunyuan Li, et al.
Annals of Hematology (2024) Vol. 103, Iss. 7, pp. 2381-2391
Closed Access | Times Cited: 1
Front‐line and second‐line treatment for mantle cell lymphoma in clinical practice: A multicenter retrospective analysis
Minna Harmanen, Marc Sorigué, Madiha Khan, et al.
European Journal Of Haematology (2024) Vol. 113, Iss. 2, pp. 218-226
Closed Access | Times Cited: 1
Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network
Linmiao Jiang, Martin Dreyling, Olivier Hermine, et al.
British Journal of Haematology (2024) Vol. 206, Iss. 1, pp. 159-166
Open Access | Times Cited: 1
Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis
Mengyang Di, Can Cui, Shalin Kothari, et al.
Blood Advances (2022) Vol. 6, Iss. 11, pp. 3339-3342
Open Access | Times Cited: 7
SOHO State of the Art Updates and Next Questions: Managing Relapsed Mantle Cell Lymphoma
Jason T. Romancik, Drew G. Gerber, Tony Zhuang, et al.
Clinical Lymphoma Myeloma & Leukemia (2022) Vol. 22, Iss. 8, pp. 557-565
Closed Access | Times Cited: 6
Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma
Narendranath Epperla, Jeffrey M. Switchenko, Veronika Bachanová, et al.
Blood Advances (2022) Vol. 7, Iss. 11, pp. 2287-2296
Open Access | Times Cited: 6
Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
Amer Beitinjaneh, Adrienne Kaufman, Yucai Wang, et al.
Current Treatment Options in Oncology (2022) Vol. 23, Iss. 11, pp. 1614-1625
Open Access | Times Cited: 5
Dismantling relapsed/refractory mantle cell lymphoma
Christine E. Ryan, Anita Kumar
Blood Reviews (2024) Vol. 67, pp. 101221-101221
Closed Access
Effect of POD24 on the prognosis of follicular and other indolent B-cell non-hodgkin lymphomas
Xiaoyan Li, Xin Wei Wang
Annals of Hematology (2024)
Open Access
Cost-effectiveness studies of brexu-cel for Relapsed/Refractory B-Cell acute lymphoblastic leukemia and Mantle Cell Lymphoma: a systematic review
Asmita Priyadarshini Khatiwada, Ahmed Mostafa Ahmed Kamel, Nathorn Chaiyakunapruk, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2024)
Closed Access
Page 1 - Next Page

Scroll to top